Results 81 to 90 of about 4,586,589 (282)

Between Reality and Representation: Exclusion of Subpopulations in Anti‐Amyloid Therapy [PDF]

Alzheimers Dement
Abstract Background Anti‐amyloid therapy has emerged as a promising approach for Alzheimer’s disease (AD), aiming to reduce beta‐amyloid plaques, a hallmark of the disease. However, global access to these therapies remains uneven, raising concerns about equity and representation in real‐world ...
Gomes A, de Almeida S, Zimmer E, Santos D, Ferreira Y, Borelli W.   +5 more
europepmc   +2 more sources

Entorhinal Astrocyte Transplants Restore Spatial Exploration and Alleviate Amyloid‐Beta Pathology in Alzheimer's Mice

Advanced Science, EarlyView.
Impaired MEC astrocytic Ca2+ signaling is associated with fragmented spatial exploration in AD mice. Region‐specific glial progenitor transplantation generates engrafted astrocytes that are accompanied by improved AQP4 polarization, reduced amyloid‐β‐associated pathology, attenuated neuroinflammation, preserved synaptic integrity, and ameliorated ...
Fengjuan Wu, Jihua Fan, Xiang Zhou, Zhiqi Yang, Mingyue Gong, Mingzhu Huang, Zhenlu Cai, Shaofan Yang, Teng Teng, Chuanyan Yang, Jin Li, Haoyu Wang, Shuangshuang Dai, Chunhai Chen, Xiaowei Chen, Manxia Wang, Kuan Zhang   +16 more
wiley   +1 more source

Combined immunotherapy with “anti-insulin resistance” therapy as a novel therapeutic strategy against neurodegenerative diseases

npj Parkinson's Disease, 2017
Protein aggregation is a pathological hallmark of and may play a central role in the neurotoxicity in age-associated neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.
Yoshiki Takamatsu, Gilbert Ho, Wakako Koike, Shuei Sugama, Takato Takenouchi, Masaaki Waragai, Jianshe Wei, Kazunari Sekiyama, Makoto Hashimoto   +8 more
doaj   +1 more source

The Impact of Anti-Amyloid Immunotherapies on Stroke Care

Anti-amyloid immunotherapies have recently emerged as treatments for Alzheimer’s disease. While these therapies have demonstrated efficacy in clearing amyloid-β and slowing cognitive decline, they have also been associated with amyloid-related
Mariel G. Kozberg, Philippe A. Bilodeau, John R. Dickson   +2 more
core   +1 more source

Anti-SAA and anti-SAA1α levels in IVIg.

, 2018
Octagam IVIg was serially diluted in sample dilution buffer (dilution range of 1.56–50 μg/ml) and analyzed for the presence of anti-SAA and anti-SAA1α antibodies using in-house ELISA. IVIg, intravenous immunoglobulin; SAA, serum amyloid A.
Katja Lakota (329716), Polonca Mali (5059424), Snezna Sodin-Semrl (329720), Matija Tomšič (5059427), Tadeja Kuret (5059433), Saša Čučnik (5059436), Sonja Praprotnik (5059430)   +6 more
core   +1 more source

14‐3‐3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity

Advanced Science, EarlyView.
Integrative multi‐cohort analyses identify 14‐3‐3γ as a biomarker and regulator of cognitive vulnerability. Experimental studies show that 14‐3‐3γ loss is associated with Tau Thr205 phosphorylation, synaptic dysfunction, and cognitive impairment, while genetic overexpression or pharmacological stabilization of 14‐3‐3γ confers protective effects in ...
Shouqiang Zhu, Xue Han, Heng Zhang, Chang Ye, Tianjiao Xia, Xiaoping Gu   +5 more
wiley   +1 more source

A Quantitative Systems Pharmacology Model That Describes Neurofilament Light Dynamics During Alzheimer's Disease Progression

CPT: Pharmacometrics & Systems Pharmacology
Neurofilament proteins are important constituents of neuronal cytoskeleton, along with microtubules. An increased concentration of neurofilament light (NfL) protein in cerebrospinal fluid (CSF) and plasma is considered a potential biomarker of axonal ...
Polina Maliukova, Tatiana Karelina
doaj   +1 more source

Ethical challenges in the clinical translation of anti-amyloid monoclonal antibodies for Alzheimer’s disease: a scoping review

Frontiers in Psychiatry
BackgroundThe development and evaluation of anti-amyloid beta monoclonal antibodies (mAbs) for the treatment of Alzheimer’s disease have been accompanied by extensive ethical debate spanning clinical trials, regulatory processes, prescribing practices ...
Alexandra Wicker, Amanda Courtright-Lim, Jon Tilburt, Jon Tilburt   +3 more
doaj   +1 more source

An Imaging and Systems Modeling Approach to Fibril Breakage Enables Prediction of Amyloid Behavior [PDF]

, 2013
Delineating the nanoscale properties and the dynamic assembly and disassembly behaviors of amyloid fibrils is key for technological applications that use the material properties of amyloid fibrils, as well as for developing treatments of amyloid ...
Xue, Wei-Feng, Xue, W-F, Radford, Sheena E., Radford, SE   +3 more
core   +1 more source

Near‐Infrared Fluorescent PROTAC Enables Theranostic Imaging and Selective Tau Degradation in Alzheimer's Disease

Advanced Science, EarlyView.
Here, we report a novel NIR fluorescent PROTAC platform that enables real‐time imaging and targeted degradation of Alzheimer's p‐Tau. Our lead compound effectively clears p‐Tau, reduces APP/Aβ, and alleviates cognitive deficits in AD mice. This work demonstrates a theranostic strategy for visualizing degradation and developing next‐generation AD ...
Ziwei Ren, Qian Yue, Ning Gao, Qiu‐Lian Hao, Yan Huo, Chuchu Li, Xinyue Leng, Lu‐Lu Sun, Maggie Pui Man Hoi, Hai‐Hao Han, Mingliang Ma, Xu‐Wen Li   +11 more
wiley   +1 more source